ABSTRACT
Advanced stage chronic renal failure (CRF) uremia represents one of the most severe metabolic "catastrophes" of the organism. The current therapeutic possibilities consist in: hemodialysis, peritoneal dialysis and renal transplantation. This paper presents the experience of the Urological Surgery, Dialysis and Renal Transplantation Center of the "Fundcni" Clinical Institute in renal transplantation, the single complete morphological and functional therapeutic option in CRF. During the last 10 years, renal transplantations with kidneys from brain dead donors (multiorgan harvesting) to an adult (1997), a child (1999), a diabetic recipient (1998) and an unephric child due to bilateral Wilms' tumor (2005) were performed at "Fundeni" Renal Transplantation Center as a national première. The immunosuppression protocols are complex, modern and adapted to the immunological risk. A number of 870 renal transplantations with 82% functionality rate of the grati at 10 years were performed and reported. Among these, 152 transplants were performed using kidneys harvested from brain dead donors. Owing to obtained results (60% of all transplanted and functional orgmans in Romania on December 2007) and to its achieved performances, the Fundeni Center represents a reference point on the European map of renal transplant.
Subject(s)
Graft Rejection/drug therapy , Immunosuppressive Agents/therapeutic use , Kidney Failure, Chronic/surgery , Kidney Transplantation , Uremia/surgery , Graft Rejection/mortality , Humans , Kidney Failure, Chronic/mortality , Severity of Illness Index , Tissue Donors , Uremia/mortalitySubject(s)
Cyclosporine/adverse effects , Glomerulonephritis, IGA/chemically induced , Graft Rejection/drug therapy , Kidney Transplantation/immunology , Kidney Transplantation/pathology , Tacrolimus/therapeutic use , ABO Blood-Group System , Adult , Azathioprine/therapeutic use , Blood Group Incompatibility , Chronic Disease , Drug Therapy, Combination , Female , Histocompatibility Testing , Humans , Immunosuppressive Agents/therapeutic use , Male , Methylprednisolone/therapeutic use , Treatment Failure , Treatment OutcomeSubject(s)
Angiography , Kidney , Living Donors , Renal Artery/diagnostic imaging , Tomography, X-Ray Computed , Aneurysm/diagnostic imaging , Humans , Image Processing, Computer-Assisted , Kidney Transplantation , Nephrectomy , Patient Selection , Renal Artery/abnormalities , Renal Artery Obstruction/diagnostic imaging , Tissue and Organ HarvestingABSTRACT
Starting from a 3D-model for the antineoplastic activity of diarylsulfonylureas several new features were proposed and tested. Both types of assayed compounds, the N-(2-pyridylsulfonyl)urea and N-(2-pyridylsulfenyl)urea derivatives, inhibited by 50% the growth of the CCRF-CEM cell line at a dosage near to 1 microM. The N -(2-pyrimidinyl) derivative of the sulfenylurea 6c showed a better profile against HT-29, K-562 and HTB-54 tumor cell lines than the corresponding sulfonylurea 6b. Structural modifications on aryl systems affected differently to the cytotoxic activity shown by the compounds against each cell line.
